Oct 2026
Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study.
Z. Gökdere, T. Şahin, I. Bilgetekin et al.
· Targeted oncology · 0 citations